

Daniel E Freedberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8149842/publications.pdf>

Version: 2024-02-01

67
papers

5,435
citations

304743

22
h-index

149698

56
g-index

70
all docs

70
docs citations

70
times ranked

10865
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Class-Specific Relationship Between Use of Immunosuppressants and Risk for Community-Acquired Clostridioides difficile Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 793-801. | 5.8 | 2 |
| 2 | Relationship Between Body Composition and Death in Patients with COVID-19 Differs Based on the Presence of Gastrointestinal Symptoms. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4484-4491. | 2.3 | 7 |
| 3 | Impact of social determinants of health on colorectal cancer screening and surveillance in the COVID reopening phase. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 739-743. | 1.6 | 9 |
| 4 | Obesity is not associated with adverse outcomes among hospitalized patients with Clostridioides difficile infection. <i>Gut Pathogens</i> , 2022, 14, 7. | 3.4 | 1 |
| 5 | Are There Bad ICU Rooms? Temporal Relationship between Patient and ICU Room Microbiome, and Influence on Vancomycin-Resistant Enterococcus Colonization. <i>MSphere</i> , 2022, , e0100721. | 2.9 | 1 |
| 6 | Evaluation of the ASPEN guidelines for refeeding syndrome among hospitalized patients receiving enteral nutrition: A retrospective cohort study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1859-1866. | 2.6 | 5 |
| 7 | Disease Course and Outcomes of COVID-19 Among Hospitalized Patients With Gastrointestinal Manifestations. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1402-1409.e1. | 4.4 | 28 |
| 8 | Type II Achalasia Is Increasing in Prevalence. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3490-3494. | 2.3 | 6 |
| 9 | Characteristics and Outcomes of Patients Undergoing Endoscopy During the COVID-19 Pandemic: A Multicenter Study from New York City. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2545-2554. | 2.3 | 16 |
| 10 | Burden and risk factors for inappropriate Clostridioides Difficile infection testing among hospitalized patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115283. | 1.8 | 2 |
| 11 | Evolution of the environmental microbiota of a new neonatal intensive care unit (NICU) and implications for infection prevention and control. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 156-161. | 1.8 | 1 |
| 12 | Characteristics and Outcomes of Endoscopies before and during the COVID-19 Pandemic in New York. <i>Digestive Diseases</i> , 2021, 39, 663-672. | 1.9 | 6 |
| 13 | Reply. <i>Gastroenterology</i> , 2021, 160, 1430-1431. | 1.3 | 3 |
| 14 | Reply. <i>Gastroenterology</i> , 2021, 160, 1900-1901. | 1.3 | 1 |
| 15 | Factors associated with delayed enteral nutrition in the intensive care unit: a propensity score-matched retrospective cohort study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 295-302. | 4.7 | 4 |
| 16 | Associations between urinary 3-indoxyl sulfate, a gut microbiome-derived biomarker, and patient outcomes after intensive care unit admission. <i>Journal of Critical Care</i> , 2021, 63, 15-21. | 2.2 | 4 |
| 17 | Famotidine and Coronavirus Disease 2019. <i>Gastroenterology</i> , 2021, 161, 360-361. | 1.3 | 4 |
| 18 | Who uses probiotics and why? A survey study conducted among general gastroenterology patients. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000742. | 2.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Probiotic Use in Celiac Disease: Results from a National Survey. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 438-445. | 0.9 | 2 |
| 20 | Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19. <i>Microbiology Spectrum</i> , 2021, 9, e0005521. | 3.0 | 31 |
| 21 | Lack of Effect of Gluten Challenge on Fecal Microbiome in Patients With Celiac Disease and Non-Celiac Gluten Sensitivity. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00441. | 2.5 | 4 |
| 22 | Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in <i>Clostridioides difficile</i> infection?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2414-2420. | 5.8 | 19 |
| 23 | Relationship Between Dietary Fiber Intake and Short-Chain Fatty Acid-Producing Bacteria During Critical Illness: A Prospective Cohort Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 463-471. | 2.6 | 26 |
| 24 | The effect of short-course antibiotics on the resistance profile of colonizing gut bacteria in the ICU: a prospective cohort study. <i>Critical Care</i> , 2020, 24, 404. | 5.8 | 6 |
| 25 | Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection. <i>Annals of Internal Medicine</i> , 2020, 173, 782-790. | 3.9 | 175 |
| 26 | Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093944. | 3.2 | 9 |
| 27 | Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032. | 30.7 | 2,300 |
| 28 | Impact of Fiber-Based Enteral Nutrition on the Gut Microbiome of ICU Patients Receiving Broad-Spectrum Antibiotics: A Randomized Pilot Trial. , 2020, 2, e0135. | | 7 |
| 29 | Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. <i>Gastroenterology</i> , 2020, 159, 1129-1131.e3. | 1.3 | 214 |
| 30 | Relationship of the Esophageal Microbiome and Tissue Gene Expression and Links to the Oral Microbiome: A Randomized Clinical Trial. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00235. | 2.5 | 13 |
| 31 | Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. <i>Scientific Reports</i> , 2019, 9, 12000. | 3.3 | 53 |
| 32 | Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1687-1693. | 2.5 | 68 |
| 33 | Impact of Gastrointestinal Panel Implementation on Health Care Utilization and Outcomes. <i>Journal of Clinical Microbiology</i> , 2019, 57, . | 3.9 | 61 |
| 34 | The Light at the End of the Tunnel. <i>Gastroenterology</i> , 2019, 156, e10-e11. | 1.3 | 0 |
| 35 | <i>Escherichia coli</i> Harboring <i>mcr-1</i> in a Cluster of Liver Transplant Recipients: Detection through Active Surveillance and Whole-Genome Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 8 |
| 36 | The microbiome. <i>Current Opinion in Anaesthesiology</i> , 2019, 32, 412-420. | 2.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Barrett's esophagus is associated with a distinct oral microbiome. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e135. | 2.5 | 49 |
| 38 | 1259. The Local Hospital Milieu and Healthcare-Associated VRE Acquisition. <i>Open Forum Infectious Diseases</i> , 2018, 5, S383-S384. | 0.9 | 0 |
| 39 | 1772. Vancomycin-Resistant Enterococcus Alters the Gastrointestinal Microbiome in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S66-S66. | 0.9 | 0 |
| 40 | Increasing Dietary Fiber Intake Is Associated with a Distinct Esophageal Microbiome. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e199. | 2.5 | 42 |
| 41 | Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. <i>Intensive Care Medicine</i> , 2018, 44, 1203-1211. | 8.2 | 121 |
| 42 | Rapid gastrointestinal loss of Clostridial Clusters IV and XIVa in the ICU associates with an expansion of gut pathogens. <i>PLoS ONE</i> , 2018, 13, e0200322. | 2.5 | 39 |
| 43 | Gut colonization with vancomycin-resistant Enterococcus and risk for subsequent enteric infection. <i>Gut Pathogens</i> , 2018, 10, 28. | 3.4 | 15 |
| 44 | Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1030-1036.e1. | 4.4 | 9 |
| 45 | The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. <i>Gastroenterology</i> , 2017, 152, 706-715. | 1.3 | 572 |
| 46 | Response to Goyal and Katner. <i>American Journal of Gastroenterology</i> , 2017, 112, 806. | 0.4 | 0 |
| 47 | An Alternative Consent Process for Minimal Risk Research in the ICU*. <i>Critical Care Medicine</i> , 2017, 45, 1450-1456. | 0.9 | 15 |
| 48 | Surgical Antibiotic Prophylaxis and Risk for Postoperative Antibiotic-Resistant Infections. <i>Journal of the American College of Surgeons</i> , 2017, 225, 631-638.e3. | 0.5 | 45 |
| 49 | Exposure to Antibiotics in the Intensive Care Unit Is Associated With Increased Risk for Bacteremia From Enteric Organisms. <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.9 | 0 |
| 50 | Receipt of Antibiotics in Hospitalized Patients and Risk for <i>Clostridium difficile</i> Infection in Subsequent Patients Who Occupy the Same Bed. <i>JAMA Internal Medicine</i> , 2016, 176, 1801. | 5.1 | 109 |
| 51 | Proton Pump Inhibitors Do Not Increase Risk for <i>Clostridium difficile</i> Infection in the Intensive Care Unit. <i>American Journal of Gastroenterology</i> , 2016, 111, 1641-1648. | 0.4 | 54 |
| 52 | Proton pump inhibitors alter the composition of the gut microbiota. <i>Gut</i> , 2016, 65, 749-756. | 12.1 | 682 |
| 53 | Microbiome as mediator: Do systemic infections start in the gut?. <i>World Journal of Gastroenterology</i> , 2015, 21, 10487. | 3.3 | 31 |
| 54 | Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. <i>Gastroenterology</i> , 2015, 149, 883-885.e9. | 1.3 | 268 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Orders for Intravenous Proton Pump Inhibitors After Implementation of an Electronic Alert. JAMA Internal Medicine, 2015, 175, 452. | 5.1 | 8 |
| 56 | Proton Pump Inhibitors and Myocardial Infarction. Gastroenterology, 2015, 149, 830-833. | 1.3 | 7 |
| 57 | The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome. Clinics in Laboratory Medicine, 2014, 34, 771-785. | 1.4 | 128 |
| 58 | Response to Abdallah et al.. American Journal of Gastroenterology, 2014, 109, 602-603. | 0.4 | 0 |
| 59 | Response to Daniell. American Journal of Gastroenterology, 2014, 109, 922-923. | 0.4 | 0 |
| 60 | Prevention of Gastric Cancer With Antibiotics: Can It Be Done Without Eradicating Helicobacter pylori?. Journal of the National Cancer Institute, 2014, 106, dju148-dju148. | 6.3 | 8 |
| 61 | A technique for skin-level gastrostomy tube placement after gastrostomy tube dislodgement. Gastrointestinal Endoscopy, 2013, 78, 963-964. | 1.0 | 0 |
| 62 | Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients. American Journal of Gastroenterology, 2013, 108, 1794-1801. | 0.4 | 88 |
| 63 | Recent Therapeutic Advances in Gastroenterology and Hepatology. Advances in Therapy, 2013, 30, 855-857. | 2.9 | 0 |
| 64 | Rectal Leiomyosarcoma After Pelvic Irradiation. Clinical Gastroenterology and Hepatology, 2013, 11, A28. | 4.4 | 6 |
| 65 | Visceral Varicella in a Patient With Chronic Lymphocytic Leukemia Treated With Fludarabine: A Case Report. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 90-92. | 0.4 | 3 |
| 66 | Clostridium difficileinfection in the community: Are proton pump inhibitors to blame?. World Journal of Gastroenterology, 2013, 19, 6710. | 3.3 | 9 |
| 67 | To eGFR or not to eGFR: here is an intern's answer. Kidney International, 2009, 76, 129-130. | 5.2 | 6 |